Multimodal mAgnetic Resonance imaGIng in Cardiovascular Disease
NCT07617844
Cardiomyopathies, Cardiomyopathy
Hangzhou, Zhejiang, China
View Trial DetailsNCT Number: NCT07449130
This is a prospective, multicenter study designed to validate a deep learning model for screening valvular heart diseases using routine, non-contrast chest computed tomography (CT) scans.
The primary objective is to evaluate the model's diagnostic performance, with the sensitivity serving as the primary efficacy endpoint. Secondary endpoints will include other performance metrics such as area under the receiver operating characteristic curve (AUC), specificity, and accuracy, etc.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Renmin Hospital of Wuhan University, Wuhan, Hubei, China
This is a prospective, multicenter study designed to validate a deep learning model for screening valvular heart diseases using routine, non-contrast chest computed tomography (CT) scans from individuals in physical examination and outpatient clinics within a hospital alliance.
The primary objective is to evaluate the model's diagnostic performance, with the sensitivity serving as the primary efficacy endpoint. Secondary endpoints will include other performance metrics such as area under the receiver operating characteristic curve (AUC), specificity, and accuracy, etc.
Participants from the target populations will undergo a routine non-contrast chest CT scan. The deep learning model will analyze these images in real-time. For those identified by the model as having moderate-to-severe heart valve disease, a confirmatory echocardiogram will be performed immediately. The echocardiogram results will serve as the reference standard for diagnosis. Statistical analyses will be performed to assess the model's performance against this reference, including calculating the 95% confidence interval for the AUC.
As this study only involves standard, low-radiation diagnostic imaging procedures (non-contrast CT and echocardiography) that are part of routine clinical care, it is considered to pose no additional relevant safety risks to participants. The total study duration is estimated to be 12 months.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
Sensitivity: Measures the proportion of patients with moderate-to-severe disease that the model correctly identifies.
Time frame: 1 year
AUC for a model distinguishing valvular disease severity. The AUC value for this model would indicate how well it can correctly identify patients with moderate-to-severe disease from those with normal-to-mild disease.
Time frame: 1 year
Accuracy: Measures the overall proportion of all patients that the model correctly classifies into either group.
Time frame: 1 year
Specificity: Measures the proportion of patients with normal-to-mild disease that the model correctly identifies.
Contact information is provided by the study sponsor or research team.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Other
Artificial-Intelligence Assisted Opportunistic Screening for Valvular Heart Disease Using Non-contrast Chest CT Scans: A Prospective, Multicenter Study
Acronym: ARTEMIS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07617844
Cardiomyopathies, Cardiomyopathy
Hangzhou, Zhejiang, China
View Trial DetailsNCT06506942
Cardiovascular Diseases, Heart Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT04442100
Cardiovascular Diseases, Heart Diseases
Tomsk, Tomsk Oblast, Russia
View Trial DetailsNCT05913908
Cardiovascular Diseases, Heart Diseases
Phoenix, Arizona, United States
View Trial Details